



# THE EXPANDING ROLE OF IMMUNOTHERAPY IN **HCC**

## COMBINING LOCOREGIONAL AND SYSTEMIC TREATMENTS IN INTERMEDIATE HCC




Immunotherapy (IO) and IO combinations are transforming the landscape for patients with advanced and intermediate HCC who are not candidates for local therapy

1<sup>st</sup> line options offer **improved long-term outcomes**



Intermediate-stage HCC may benefit from multimodal strategies, **combining IO with locoregional therapies (LRTs)** to address both visible and invisible disease, enhancing immune response, and optimising tumour control

**A multidisciplinary approach** is crucial to determine which patients with intermediate HCC may benefit from multimodal combinations



**IO + LRT combinations, such as TACE plus IO, show promise for patients with intermediate HCC**

**Lenvatinib + pembrolizumab + TACE**

VS

**TACE**



**Durvalumab +/- bevacizumab + TACE**

VS

**TACE**



**IO + LRT combinations demonstrate improved PFS**

IO + LRT combinations show manageable safety profiles

OS data are awaited

**COR2ED**

Go to [COR2ED.COM](https://COR2ED.COM) for more information and resources

